The first example of the success of this strategy has been the POLARIX study, assessing polatuzumab—an ADC conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) and targeting CD79b—in previously untreated patients with DLBCL. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.